IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories share news and announcements
771 announcements, routine notices left out, newest first. Page 16 of 16.
Oct 2007
31 Oct · Disclosure
Ipca Laboratories Ltd. has informed the Exchange vide its letter dated October 29, 2007 that : "The Compensation Committee of the Board of Directors in their meeting held on 29th October, 2007 have granted 1,10,000 (One Lac Ten Thousand Only) options under Ipca Laboratories Ltd - Employee Stock Option Scheme - 2006 (ESOS) to selected Employees of the Company and its subsidiary. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Oct · Dividend
Ipca Laboratories Ltd. has informed the Exchange that the board of directors in its meeting held on October 29, 2007 has declared an interim dividend of 35% for the financial year 2007-08.18 Oct · Board meeting
Inter-alia, to consider the following: 1) Unaudited Financial Results for the quarter and half year ended September 30, 2007; and 2) Interim Dividend for the financial year 2007-08. Further, the Company has decided to fix November 07, 2007 as the 'Record Date' for the Members entitlement of interim dividend for the financial year 2007-08 that may be declared at the said Board Meeting.5 Oct · Disclosure
Premchand Godha, for and on behalf of himself, Kaygee Investments Pvt. Ltd. & Exon Laboratories Pvt. Ltd. has informed the Exchange that he alongwith Kaygee Investments Pvt. Ltd. & Exon Laboratories Pvt. Ltd. propose to acquire 15,22,402 Equity Shares representing 6.09% of the total paid up equity Share capital of Ipca Laboratories Ltd. from the following transferor: Chandurkar Investments Pvt. Ltd. The mode of proposed acquisition is by way of Inter-se Transfer and the date of proposed acquisition is between October 12, 2007 to October 17, 2007. The proposed acquisition price per share is between Rs.650/- to Rs.710/-. The shareholding of Premchand Godha, Kaygee Investments Pvt. Ltd. & Exon Laboratories Pvt. Ltd. after the proposed acquisition would be 75,01,842 shares aggregating to 30.01% of the shares/voting rights of Ipca Laboratories Ltd. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
14 Sep · Miscellaneous
Ipca Laboratories Ltd. has informed the Exchange that: "Ipca Laboratories Limited has received approval for its Anti-malarial finished product formulation, Artesunate Tablets 50mg under WHO's Prequalification Programme. The product is now listed in the WHO Pre-qualification product list, dated 30 August, 2007". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Sep · Business
Ipca Laboratories Ltd. has informed the Exchange that "The Company has acquired 100% shareholding of a small formulation product dossier registration-cum-distribution company in Australia. This company is currently holding 5 formulation registration dossiers in that country. This Australian company is also having a wholly owned formulation dossier registration-Cum-distribution company in New Zealand currently holding 3 formulation registration dossiers in New Zealand. Acquisition of these companies will help Ipca in strengthening its existing formulations business in Australia and New Zealand".
Aug 2007
27 Aug · Business
Ipca Laboratories Ltd. has informed the Exchange that Central Drug Research Institute (CDRI) has entered into a collaborative-cum-license agreement with Ipca for further development of its compound 99/411, a promising synthetic substitute for drugs based on Artemisinin derived from the plant Artemisia annua. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Aug · Miscellaneous
Ipca Laboratories Ltd. has informed the Exchange that Ohm laboratories, Inc. (Ohm), wholly owned subsidiary of Ranbaxy Laboratories Ltd. has received approval from U.S. Food and Drugs Administration. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
25 Jul · Miscellaneous
Ipca Laboratories Ltd. had informed the Exchange regarding strategic alliance with Ranbaxy Pharmaceuticals Inc. (Ranbaxy) based in Jacksonville, Florida (USA), a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), India's largest pharmaceutical company. The Company has now informed the Exchange that wholly owned subsidiary of RLL has now received approval from U.S. Food and Drugs Administration to manufacture and market Hydrochlorothiazide tablets in USP 12.5mg, 25mg and 50mg in the US market. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jul · Meeting
Ipca Laboratories Ltd. has informed the Exchange that the members of the Company at the Annual General Meeting held on July 20, 2007 have accorded their approval for the following: (1) Payment of dividend on the equity shares. (2) Re-appointment of Mr. A.K. Jain, Mr. Premchand Godha and Mr. R.S. Hugar as the Directors of the Company. (3) Re-appointment of Mr. Natvarlal Vepari & Co, /Chartered Accountants as the Auditors of the Company to hold office till date of conclusion of the next AGM. (4) Amendment to Employee Stock Option Scheme (ESOS). (5) Extension of benefits of ESOS to Employees and Directors of Subsidiary Companies. (6) Increase in the remuneration payable to Mr. Pranay Godha as President-APIs & Generics.13 Jul · Board meeting
Meeting on 20 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jun 2007
19 Jun · Miscellaneous
Ipca Laboratories Ltd. has informed the Exchange that: "Ipca Laboratories Ltd. (Ipca) has received approval from U.S. Food and Drugs Administration to market Hydroxychloroquine Sulfate Tablets USP - 200 mg in the US market. Total annual market sales for Hydroxychloroquine Sulfate tablets in U.S. were US $ 50 millions (IMS-MAT : March ' 07)". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jun · Meeting
Ipca Laboratories Ltd. has informed the Exchange that the Annual General Meeting of the Company will be held on July 20, 2007 to transact the business as set out in the notice convening the said Annual General Meeting which will be mailed to all the shareholders of the Company. The company has further informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from July 12, 2007 to July 20, 2007, both days inclusive for the purpose of AGM and Dividend @ Rs.4.00 per share (40%).
May 2007
25 May · Business
Ipca Laboratories Ltd. has informed the Exchange regarding a press release dated May 25, 2007, with respect to the Board Meeting held on May 25, 2007 for the Audited Financial Results of the Company for the financial year ended March 31, 2007. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 May · Dividend
Ipca Laboratories Ltd. has informed the Exchange that the Board of Directors at its meeting held on May 25, 2007 recommended Final dividend of Rs.4/- per share (40%). Total dividend for financial year Rs.7.50 per share (75%).18 May · Board meeting
Inter - alia, to consider : (1) the Audited Financial Results for the financial year ended March 31, 2007 ; and (2) recommendation of final dividend for financial year ended March 31, 2007.
Apr 2007
5 Apr · E-mail ID for Investor Complaints
Ipca Laboratories Ltd. has informed the Exchange that "we have dedicated the following e-mail ID where the investors can contact the company with all their queries; [email protected]."5 Apr · Results
Ipca Laboratories Ltd. has informed the Exchange that "it has been decided by the Company to publish its Audited Financial Results for the financial year ended 31st March, 2007 on or before 30th June, 2007."
Feb 2007
6 Feb · Miscellaneous
Ipca Laboratories Ltd. has informed the Exchange that "The Company has decided to close down its wholly owned investment holding subsidiary companies by the name : (1) Solway Investments Ltd. (2) Sundridge Management Ltd. incorporated in the Republic of Mauritius with effect from close of business hours on 31st January, 2007. Solway Investments Ltd. and Sundridge Management Ltd. were holding 50% each in the paid-up equity share capital of Ipca Pharma Nigeria Ltd., Nigeria and National Druggists (Pty) Ltd., South Africa, formulations distribution companies which are engaged in the distribution of formulations manufactured in India by the company respectively in Nigeria and South Africa. The Company has now purchased the entire 100% paid up share capital of Ipca Pharma Nigeria Ltd. and National Druggist (Pty) Ltd. from Solway Investment Ltd. and Sundridge Management Ltd. and thus converted the said Ipca Pharma Nigeria Ltd., Nigeria and National Druggists (Pty) Ltd., South Africa as its wholly owned subsidiary companies".
Jan 2007
15 Jan · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 3rd Quarter and nine months ended December 31,2006.2 Jan · Miscellaneous
Ipca Laboratories Ltd. has informed the Exchange that "IPCA- Ranbaxy Alliance Receive U.S. FDA Marketing Approval For Atenolol Tablets". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)." For more details click here.